Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACITRACIN-NEOMYCIN-POLYMYXIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Treatment of superficial bacterial infections of the skin and mucous membranes (e.g., wounds, burns, impetigo, folliculitis),Prophylaxis of minor skin abrasions and wounds to prevent infection,Off-label: Use in conjunctival irrigation or ophthalmic infections (as combination ophthalmic preparations)
Topical treatment of bacterial infections of the skin and eye (e.g., conjunctivitis, keratitis, blepharitis),Prophylaxis of minor wounds, cuts, and abrasions
Apply topically to affected area 2-5 times daily.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
Bacitracin: 1.5 hours (prolonged in renal impairment); Neomycin: 2-3 hours (accumulates with renal dysfunction); Polymyxin B: 6-9 hours (increased in renal impairment).
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
Not extensively metabolized. Systemic absorption from topical application is minimal; absorbed drug may undergo hepatic metabolism or be excreted renally unchanged.
Not systemically absorbed after topical administration; no significant metabolism.
Bacitracin: primarily renal (>90% unchanged); Neomycin: renal (30-50% unchanged) with non-renal clearance; Polymyxin: renal excretion of parent drug (60-80% unchanged) with some biliary and fecal elimination.
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Bacitracin: <10% bound to plasma proteins; Neomycin: 0-30% bound; Polymyxin B: 50-70% bound, primarily to alpha-1-acid glycoprotein and lipoproteins.
Neomycin: 0-20%; polymyxin B: 60-80% (alpha-1-acid glycoprotein, albumin); bacitracin: <5%. Combined: ~40-50% bound overall.
Bacitracin: 0.3 L/kg (confined to extracellular fluid); Neomycin: 0.2-0.3 L/kg (low tissue penetration except renal cortex); Polymyxin B: 0.7-1.0 L/kg (extensive tissue binding).
Neomycin: ~0.25 L/kg; polymyxin B: ~0.5 L/kg; bacitracin: ~0.3 L/kg. Combined Vd ~0.3-0.5 L/kg, reflecting limited distribution mainly to extracellular fluid.
Oral: negligible (<1%) for all three components; topical: minimal systemic absorption via intact skin (<0.5%); ophthalmic/otic: minimal absorption via mucosal surfaces.
Topical/ophthalmic/otic: negligible systemic absorption (<0.1%).
No systemic absorption; no dosage adjustment required.
No systemic absorption with typical topical use; no adjustment necessary. For extensive use on damaged skin, monitor renal function and adjust if needed; no specific GFR-based guidelines.
No systemic absorption; no dosage adjustment required.
No adjustment needed for topical use. No systemic effects expected.
Apply topically to affected area 2-5 times daily; same as adult dose.
Same as adult dosing for topical use. For neonates, use with caution on large surface areas; avoid prolonged use.
Apply topically to affected area 2-5 times daily; same as adult dose.
No specific age-related adjustments. Use with caution on fragile skin; apply sparingly to avoid systemic absorption.
Not applicable for topical formulations. However, systemic use of bacitracin (rare) may cause nephrotoxicity and anaphylactic reactions. Neomycin may cause ototoxicity and nephrotoxicity with systemic absorption.
None.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Topical use may cause allergic contact dermatitis, especially with neomycin.,Avoid application to large areas, open wounds, or damaged skin due to potential systemic absorption and toxicity.,Use with caution in patients with renal impairment or pre-existing hearing loss (neomycin component).,Ototoxicity and nephrotoxicity may occur if significant systemic absorption occurs.
Prolonged use may result in overgrowth of nonsusceptible organisms including fungi.,Neomycin is ototoxic and nephrotoxic if absorbed systemically (e.g., applied to large areas of damaged skin).,Avoid contact with eyes other than for ophthalmic use.,Cross-allergenicity among aminoglycosides exists.
Hypersensitivity to any component (bacitracin, neomycin, polymyxin B) or other aminoglycosides/polypeptide antibiotics.,Ophthalmic use in eyes with corneal abrasions or perforation (relative).,Known history of neomycin-associated ototoxicity or nephrotoxicity.
Hypersensitivity to any component of the product.,Otic use if tympanic membrane is perforated (risk of ototoxicity).
No significant food interactions; topical application minimizes systemic absorption. No dietary restrictions.
No known food interactions with topical application.
Bacitracin-Neomycin-Polymyxin is a topical combination with negligible systemic absorption; thus, fetal risk is minimal. No known teratogenic effects reported; animal studies for individual components show no fetal harm at systemic doses. However, neomycin has theoretical risk of ototoxicity if systemically absorbed, but topical use is considered low risk. FDA Pregnancy Category C for components, but topical use deemed safe.
No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No known association with congenital anomalies.
Minimal systemic absorption after topical application; excretion into breast milk is unlikely. M/P ratio not determined; safe for use during breastfeeding if applied to small areas and not to open wounds.
Minimal systemic absorption suggests negligible excretion into breast milk; M/P ratio not determined. Considered compatible with breastfeeding by AAP; avoid application to breast area to prevent infant ingestion.
No dosing adjustments necessary for pregnancy. Pharmacokinetic changes due to pregnancy (e.g., increased skin blood flow, hydration) are not clinically significant for this topical combination. Standard topical application is appropriate.
No dosage adjustment required for topical use; systemic absorption is negligible. Use standard dosing as per non-pregnant adults.
Triple antibiotic ointment (bactiracin-neomycin-polymyxin) is first-line for prophylaxis of minor skin infections; avoid use on large areas, deep wounds, or burns due to risk of systemic absorption and nephrotoxicity. Neomycin carries high risk of allergic contact dermatitis; consider alternative in patients with known hypersensitivity. Topical use only; not for ophthalmic or intranasal application due to polymyxin ocular toxicity. Synergistic coverage includes Gram-positive (bacitracin), Gram-negative (polymyxin), and broad-spectrum (neomycin).
OTC triple antibiotic ointment; avoid use on deep wounds, puncture wounds, or animal bites due to risk of toxicity and lack of efficacy. Neomycin carries the highest risk of allergic contact dermatitis among topical antibiotics; consider patch testing if prolonged use needed. Polymyxin B can cause neurotoxicity and nephrotoxicity if applied to large wounds or damaged skin. Not for use in eyes, ears, or mucous membranes. Do not exceed 7 days of continuous use.
Apply a thin layer to clean, minor cuts, scrapes, or burns 1-3 times daily.,Do not use on large body areas, deep puncture wounds, animal bites, or serious burns.,Stop use and consult doctor if rash, irritation, or signs of infection (worsening redness, swelling, pus) develop.,Avoid use on eyes, nose, or mouth; if contact occurs, rinse thoroughly with water.,Tell your doctor if you have kidney problems or are allergic to any of the ingredients (bacitracin, neomycin, polymyxin B).
Clean the affected area before applying a thin layer of ointment 1-3 times daily.,Do not use on large areas of skin, deep cuts, puncture wounds, or animal bites unless directed by a doctor.,Do not apply to eyes, nose, mouth, or inside ears.,Stop use and consult a doctor if rash or allergic reaction develops, condition worsens, or persists for more than 7 days.,Keep out of reach of children; seek medical attention if accidentally ingested.
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacitracin."
"Bacitracin may increase the nephrotoxic activities of Colistimethate."
"Bacitracin may increase the nephrotoxic activities of Streptomycin."
"Cisatracurium, a non-depolarizing neuromuscular blocking agent (NMBA), competitively blocks nicotinic acetylcholine receptors at the neuromuscular junction, causing skeletal muscle paralysis. Polymyxin B, a polypeptide antibiotic, can potentiate this neuromuscular blockade by reducing presynaptic acetylcholine release and stabilizing postsynaptic membranes, leading to prolonged and enhanced neuromuscular blockade. This interaction increases the risk of prolonged muscle paralysis, respiratory depression, and apnea, especially in patients with renal impairment or those receiving other NMBAs."
"Mecamylamine, a ganglionic blocking agent, potentiates the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic. This interaction occurs through additive or synergistic inhibition of neuromuscular transmission, potentially leading to prolonged or intensified muscle relaxation, respiratory depression, and apnea. The clinical outcome may include enhanced toxicity, especially in patients with renal impairment or those receiving concurrent anesthetics or other neuromuscular blocking agents."
"Decamethonium, a depolarizing neuromuscular blocker, enhances the neuromuscular blocking effects of Polymyxin B, a polypeptide antibiotic that can also cause neuromuscular blockade via direct membrane stabilization and calcium channel inhibition. This additive pharmacodynamic interaction can lead to prolonged or enhanced muscle weakness, potentially resulting in respiratory paralysis and apnea. Clinically, this combination increases the risk of acute respiratory failure and may prolong recovery from neuromuscular blockade."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACITRACIN-NEOMYCIN-POLYMYXIN vs BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE, answered by our medical review team.
BACITRACIN-NEOMYCIN-POLYMYXIN is a Aminoglycoside Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin and polymyxin B are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting protein synthesis, while polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides and phospholipids, leading to increased permeability and cell death.. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is a Aminoglycoside Antibiotic that works by Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of m RNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACITRACIN-NEOMYCIN-POLYMYXIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE depend on the specific clinical indication. These are both Aminoglycoside Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACITRACIN-NEOMYCIN-POLYMYXIN is: Apply topically to affected area 2-5 times daily.. The standard adult dose of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is: Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BACITRACIN-NEOMYCIN-POLYMYXIN and BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bacitracin. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BACITRACIN-NEOMYCIN-POLYMYXIN is classified as Category A/B. Bacitracin-Neomycin-Polymyxin is a topical combination with negligible systemic absorption; thus, fetal risk is minimal. No known teratogenic effects reported; animal studies for i. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE is classified as Category A/B. No evidence of teratogenicity in first trimester; animal studies show no fetal harm. Second and third trimester risk is low due to minimal systemic absorption from topical use. No . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.